Product News
Filter News
Found 190,807 articles
-
Renal cell carcinoma is also called renal cell cancer or renal cell adenocarcinoma. Approximately 90% of all kidney cancers are renal cell carcinomas.
-
Steps have been taken to safeguard the cancer center, including development of a cutting-edge approach to Enterprise Risk Management.
-
Eli Lilly and Company announced results from its COAST-X Phase III clinical trial of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA) in patients who had no previous disease-modifying anti-rheumatic drug (bDMARD) treatment.
-
Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.
-
The two companies will combine their expertise to drive new immunology candidates toward the clinic.
-
Liht Cannabis Corp. Announces Share Exchange Agreement with Late-Stage Applicant "Buds For You Inc." and Corporate Update
4/22/2019
Liht Cannabis Corp. (CSE: LIHT) (OTCQX: LIHTF) ("Liht" or the "Company"), a Nevada licensed cannabis cultivator and producer is pleased to announce that on April 18, 2019, it has entered into a Share Exchange Agreement (the "Agreement") with Buds For You Inc. ("Buds For You") – a late-stage cannabis cultivation, processing, and sales license applicant under the Cannabis Act – to acquire all issued and outstanding shares of Buds for You.
-
Inova Extends Partnership with Omnicell to Enhance Efficiency and Safety in Medication Management
4/22/2019
Automation for Sterile Compounding and Patient Care Areas Support Improved Clinical Care
-
Water Environment Federation Launches Daily News Service with SmartBrief
4/22/2019
Publication to provide targeted news; career opportunities; and educational resources for thousands of water quality professionals
-
Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
4/22/2019
OP0201 Was Safe and Well-Tolerated in Healthy Adults and Adults with Acute Otitis Media
-
VisCardia Announces Completion of Enrollment and Three Month Follow-Up Visits for Its VisONE® Heart Failure Pilot Study
4/22/2019
VisCardia Inc. announced it has completed enrollment and three month follow-up visits of the company’s VisONE® implantable system pilot for medical refractory heart failure patients with reduced ejection fraction and preserved ventricular synchrony.
-
Consumers expect to keep protein on their shopping lists as part of a healthy and sustainable diet, according to new survey
4/22/2019
Meat, fish and eggs can be an important part of a healthy and environmentally responsible diet, say consumers in new global research from Cargill.
-
Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019
4/22/2019
Moleculin Biotech, Inc. announced it will host a conference call to discuss its significant discovery for lung cancer, FDA Fast Track Designation and recent corporate events.
-
Visioneering Technologies, Inc. and Lambda-X Develop Software to Show Accurate Power Profile of NaturalVue Multifocal Contact Lenses
4/22/2019
Key data output describes the NaturalVue Multifocal power curve and its patented design
-
Statement from Peter Marks, M.D., Ph.D., director of FDA's Center for Biologics Evaluation and Research, on FDA's continued confidence in the safety and effectiveness of the measles, mumps, and rubella (MMR) vaccine
4/22/2019
The FDA is a public health agency that always strives to use the best available scientific evidence to promote and protect the well being of individuals.
-
TILT Announces Expansion of Jupiter Distribution in California
4/22/2019
Jupiter’s proprietary inhalation technology continues rapid growth with the integration of Baker and Blackbird software and services
-
Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
4/22/2019
Eli Lilly and Company announced that Taltz® met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis in patients who are biologic disease-modifying anti-rheumatic drug-naïve.
-
Indegene AI-driven Next Generation Commercialization Platform Launches YospralaTM
4/22/2019
Indegene, a leading transformational partner to lifesciences industry, today disrupted the traditional biopharma launch and commercialization model with the next generation AI-driven launch of YospralaTM for secondary CAD and stroke prevention.
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
4/22/2019
Approval Based on Results of KEYNOTE-426, Where KEYTRUDA in Combination With Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib
-
Barco® Selects The Pollack PR Marketing Group As Agency Of Record After A Competitive Review
4/22/2019
The Pollack PR Marketing Group announced that Barco Uniforms has selected PPMG as its agency of record.
-
Oakrum Pharma and Biophore Announce Product Development and Commercialization Partnership
4/22/2019
Oakrum Pharma, LLC announced that it has entered into an agreement with Biophore India Pharmaceuticals Pvt. to develop and manufacture two prescription generic pharmaceutical products that are intended to be commercialized in the U.S. under the Oakrum label.